Table 3A.

Unadjusted odds ratio in lymph node metastasis predictive model.

	Variable	Odds ratio	p-value	AUC
	PSA (Preoperative)	1.06 (1.02–1.10)	0.0070	0.79 (0.67–0.91)
	Primary Gleason Score	3.07 (2.27–4.17)	<0.0001	0.76 (0.73–0.81)
	Clinical Tumor stage	1.23 (1.04–1.45)	0.0158	0.59 (0.51–0.66)
ELR+ Chemokine Receptor	CXCR1	0.51 (0.31–0.86)	0.0115	0.61 (0.55–0.68)
	CXCR2	0.68 (0.45–1.02)	0.0595	0.57 (0.50–0.64)
ELR+ Chemokine	CXCL5	0.16 (0.03–0.81)	0.0276	0.59 (0.52–0.65)
	CXCL8	0.83 (0.59–1.18)	0.3110	0.59 (0.51–0.66)
ELR− Chemokine Receptor	CXCR3	1.34 (1.08–1.65)	0.0066	0.58 (0.50–0.66)
	CXCR4	1.33 (1.08–1.63)	0.0075	0.57 (0.49–0.64)
	CXCR5	1.24 (1.01–1.54)	0.0417	0.59 (0.51–0.66)
	CXCR7	1.40 (1.07–1.83)	0.0127	0.57 (0.49–0.64)
ELR− Chemokine	CXCL9	1.32 (1.08–1.61)	0.0077	0.62 (0.55–0.69)
	CXCL10	1.50 (1.22–1.85)	0.0001	0.64 (0.57–0.71)
	CXCL11	1.34 (1.10–1.63)	0.0039	0.61 (0.55–0.68)

AUC, Area under the curve; PSA, Prostate-Specific Antigen.

The significance of the preoperative PSA concentration, clinical tumor stage, and primary Gleason score with the expression of ELR⁻ CXC and ELR⁺ CXC chemokines/receptors was analyzed by univariate logistic regression analysis.